Immunocore Reports Updated Phase 1 Brenetafusp Data Showing Brenetafusp Was Well Tolerated In Monotherapy And In Combination With Anti-PD1 And Demonstrated A Durable Clinical Benefit
Immunocore Reports Updated Phase 1 Brenetafusp Data Showing Brenetafusp Was Well Tolerated In Monotherapy And In Combination With Anti-PD1 And Demonstrated A Durable Clinical Benefit
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.